hermo Fisher Scientific has announced its intention to buy Patheon NV.
Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced its intention to buy Patheon NV (Amsterdam, The Netherlands), a manufacturer of drugs for clinical trials, for $5.2 billion as the company seeks to expand its products and services for the biopharma industry.
Thermo Fisher Chief Executive Marc Casper described the deal as a “hand in glove fit to… our fastest growing part of the business.”
The deal is expected to be completed by the end of the year, and Casper believes the purchase will allow for greater growth potential in the long run with “very interesting opportunities to build out their footprint in AsiaâPacific.” An area Thermo Fisher feels it has yet to penetrate.
“It’s really about expanding our capabilities,” said Casper. “We want to be able to offer our customers a menu of services.”
The buyout of Patheon is expected to more than double Thermo Fisher’s sales in the biopharma market.
For more information please visit, www.thermofisher.com
Inside the Laboratory: The Chromatography Laboratory at the University of Rouen
April 18th 2024In this edition of “Inside the Laboratory,” Pascal Cardinael and Valérie Agasse of the University of Rouen in Mont‑Saint-Aignan, France, discuss their laboratory’s work with miniaturizing gas chromatography (GC) columns and systems to improve on-site air analysis of volatile organic compounds (VOCs).